Back to Search
Start Over
Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma
- Source :
- Medical oncology (Northwood, London, England). 17(3)
- Publication Year :
- 2000
-
Abstract
- A patient with advanced and chemotherapy-refractory nodal marginal zone B-cell lymphoma was given a course of chimeric CD 20 monoclonal antibody Rituximab. Partial response was observed without any major toxicities. Retreatment with Rituximab for disease progression six months after the first course led to partial remission. Adjuvant radiotherapy was given for the residual disease and, currently, patient's disease remains stable eight months after the second course of Rituximab. This case demonstrates the therapeutic efficacy and feasibility of retreatment with Rituximab for relapsed or refractory low grade lymphoma.
- Subjects :
- Oncology
Male
Cancer Research
medicine.medical_specialty
Pathology
Lymphoma, B-Cell
medicine.drug_class
medicine.medical_treatment
Antineoplastic Agents
Monoclonal antibody
Antibodies, Monoclonal, Murine-Derived
immune system diseases
hemic and lymphatic diseases
Internal medicine
medicine
Humans
Nodal marginal zone B cell lymphoma
Chemotherapy
Hematology
business.industry
Antibodies, Monoclonal
General Medicine
Middle Aged
Marginal zone
medicine.disease
Lymphoma
Radiation therapy
Treatment Outcome
Disease Progression
Rituximab
Radiotherapy, Adjuvant
business
medicine.drug
Subjects
Details
- ISSN :
- 13570560
- Volume :
- 17
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Medical oncology (Northwood, London, England)
- Accession number :
- edsair.doi.dedup.....9d4ec7885558e15557eb60f17d1c7ac4